 "Cadila Healthcare says Changodar plant has got no USFDA observation")
Ahmedabad-based pharma major Cadila Healthcare on Friday informed the stock exchanges that no observations were issued by the US Food and Drugs Administration (FDA) against its topicals manufacturing plant at Changodar.
The plant was inspected by the US FDA between April 3 and April 7. According to a notice to the BSE, no observation (483) was issued. The company has filed 17 products with the US FDA from the site. Shares of Cadila Healthcare ended the session, up 1.5 per cent, at ~454.85 a share on the BSE. Earlier, in February, the company's Moraiya unit too did not receive any observations from the US FDA.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%